Recently appointed Chairman John Williford is dead at the age of 61, company announces March 10. Williford was named to the board of the Abita Springs, La.-based ophthalmic products firm in June 1992 and became chairman in February 1993 ("The Pink Sheet" March 8, In Brief). Akorn has not announced its plans for a successor to Williford.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth